NCT02919605View on ClinicalTrials.gov

Efficacy and Safety of Pentamidine (7mg/kg) for Patients With Cutaneous Leishmaniasis Caused by L. Guyanensis

PHASE2CompletedINTERVENTIONAL
Enrollment

159

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
Cutaneous Leishmaniases
Interventions
DRUG

Single dose of Pentamidine

The patients will come to the hospital to take a single dose of the Pentamidine.

DRUG

Two doses of Pentamidine

The patients will come to the hospital to take two doses of the Pentamidine, in interval of one week between them.

DRUG

Three doses of Pentamidine

The patients will come to the hospital to take three doses of the Pentamidine, in interval of one week between them.

All Listed Sponsors
lead

Fundação de Medicina Tropical Dr. Heitor Vieira Dourado

OTHER

NCT02919605 - Efficacy and Safety of Pentamidine (7mg/kg) for Patients With Cutaneous Leishmaniasis Caused by L. Guyanensis | Biotech Hunter | Biotech Hunter